# Deep Extraction Batch 3 Research Workspace Review - 2026-06-26

Purpose: review the third diabetes/obesity deep-extraction batch against the Research Workspace quality bar: evidence map readiness, judgment quality, translational value, and explicit evidence boundaries.

This review follows the desktop workflow note: a high-quality output should not be a literature summary. It should convert references into Paper Cards, cluster them into an Evidence Map, state research judgments, identify translational value, and preserve gaps / next moves.

## Scope

The user supplied 10 third-batch titles:

| Title | Canonical Handling | Review State |
|---|---|---|
| Feline comorbidities: Pathophysiology and management of the obese diabetic cat | `src-diabetes-005`; duplicate alias `src-diabetes-119` | ready |
| Comparative Aspects of Human, Canine, and Feline Obesity and Factors Predicting Progression to Diabetes | `src-diabetes-028`; obesity alias `src-obesity-095` | ready |
| GLUT4 but not GLUT1 expression decreases early in the development of feline obesity | `src-obesity-027` | ready, with full-article audit gap |
| Insulin Sensitivity Decreases with Obesity, and Lean Cats with Low Insulin Sensitivity are at Greatest Risk of Glucose Intolerance with Weight Gain | `src-obesity-008` | ready |
| Obesity-induced changes in gene expression in feline adipose and skeletal muscle tissue | `src-obesity-022` | blocked: supplied desktop body duplicated `src-obesity-008` |
| The cat as a model for human obesity: insights into depot-specific inflammation associated with feline obesity | `src-obesity-011` | ready |
| Metabolic Profiles of Feline Obesity Revealed by Untargeted and Targeted Mass Spectrometry-Based Metabolomics Approaches | `src-obesity-030` | ready |
| Association between Gut Microbiota and Metabolic Health and Obesity Status in Cats | `src-obesity-049` | ready |
| The effect of obesity and subsequent weight reduction on cardiac morphology and function in cats | `src-obesity-066` | ready |
| Identifying the target population and preventive strategies to combat feline obesity | `src-obesity-005` | ready |

Operational status:

- Valid deep extracts processed: 9/9.
- Blocked title/body mismatch: 1 (`src-obesity-022`).
- Ready source / alias cards with local raw artifact links: 11/11 relevant route cards.
- Ready source / alias cards with parsed `source_passages`: 11/11 relevant route cards.
- Ready source / alias cards with Research Mode V2 fields: 11/11 relevant route cards.
- Third-batch obesity items removed from stale research-depth queue: `src-obesity-030`, `src-obesity-049`, `src-obesity-066`.

## Evidence Map Readiness

This batch can support a focused Research Workspace brief on:

**Feline Obesity, Insulin Resistance, and Translational Evaluation Endpoints**

The evidence map should be clustered by research role rather than by title order.

| Cluster | Sources | What It Supports | What It Must Not Overclaim |
|---|---|---|---|
| Obesity-to-diabetes mechanism architecture | `src-diabetes-028`, `src-obesity-008`, `src-obesity-027`, `src-diabetes-005` | obesity can drive insulin resistance, but diabetes progression requires beta-cell / hepatic compensation failure and presentation-state management | obesity or insulin resistance alone as deterministic diabetes prediction |
| Early insulin-resistance and glucose handling endpoints | `src-obesity-008`, `src-obesity-027` | insulin sensitivity, glucose effectiveness, IVGTT/MINMOD-type measures, glucose/insulin AUC, tissue GLUT4 as research endpoints | clinical screening thresholds or owner-facing interpretation rules |
| Adipose tissue inflammation and depot biology | `src-obesity-011` | chronic natural obesity model, local adipose inflammation, SAT/VAT model boundary, immune/adipokine endpoints | systemic cytokine claims, insulin-sensitivity claims, or human VAT-centric direct import |
| Metabolic phenotyping and candidate biomarkers | `src-obesity-030`, `src-obesity-049` | MHO/MUO framing, amino acid/lipid/metabolomics signals, selected microbiota-family associations | diagnostic panels, causal biomarkers, microbiome interventions |
| Cardiac morphology and diagnostic confounding | `src-obesity-066` | obesity as LV wall-thickness / HCM interpretation confounder; weight-reduction follow-up as partial reversibility signal | obesity causes primary HCM; weight loss reverses all cardiac dysfunction |
| Prevention and target population | `src-obesity-005` | post-gonadectomy 5-12 month kittens as priority prevention group; growth monitoring and DER-based feeding workflow | adult weight-loss diet logic in kittens; universal DER prescriptions |
| Obese diabetic cat management | `src-diabetes-005` | staged management: stabilize glycemia / preserve muscle before caloric restriction when active disease-related weight loss is present | immediate caloric restriction for every obese diabetic cat |

## Core Judgments

1. Feline obesity is not one evidence layer. It separates into mechanism, metabolic phenotype, tissue inflammation, cardiology interpretation, and prevention.

2. The strongest translational spine is not "obesity causes diabetes." It is: obesity increases insulin resistance; some cats compensate; decompensation depends on beta-cell reserve, hepatic glucose output, baseline insulin sensitivity, and presentation state.

3. BCS and body weight are useful entry points, but this batch supports a richer endpoint matrix: IVGTT/MINMOD, glucose effectiveness, insulin sensitivity, insulin AUC, GLUT4 expression, adiponectin, triglycerides, selected metabolomics, selected microbiota families, LVWT, diastolic function, and kitten growth trajectory.

4. MHO/MUO is useful as research architecture, not as a validated feline clinical classification. Both `src-obesity-030` and `src-obesity-049` should be used to describe candidate phenotype layers, not diagnostic panels.

5. Obesity-related cardiac findings are high translational value for interpretation of echocardiography and HCM-like phenotypes, but the evidence remains observational and should be labeled as diagnostic-context evidence.

6. Prevention output should be built around the post-gonadectomy kitten window, not adult weight-loss logic.

## Methods And Endpoints Inventory

| Endpoint / Method Layer | Candidate Sources | Use In Research Workspace |
|---|---|---|
| Body condition / body weight / DEXA | `src-obesity-008`, `src-obesity-066`, `src-obesity-005` | entry phenotype, body composition, growth monitoring, weight-reduction response |
| IVGTT / MINMOD / insulin sensitivity | `src-obesity-008`, `src-obesity-027`, `src-diabetes-005` | mechanism endpoint for obesity-induced insulin resistance |
| Glucose effectiveness / glucose tolerance | `src-obesity-008`, `src-obesity-027` | early decompensation endpoint, not clinical threshold |
| Tissue glucose transport | `src-obesity-027` | GLUT4 versus GLUT1 mechanism endpoint |
| Beta-cell / hepatic compensation | `src-diabetes-028` | progression-model architecture |
| Adipokines / inflammatory markers | `src-obesity-011`, `src-obesity-030`, `src-obesity-049` | phenotype layer, not causal closure |
| Serum metabolomics | `src-obesity-030` | candidate biomarker layer |
| Fecal microbiota | `src-obesity-049` | candidate association layer |
| Echocardiography / LVWT / diastolic function | `src-obesity-066` | HCM confounder and obesity cardiac morphology layer |
| Prevention workflow | `src-obesity-005` | owner/vet communication, growth curves, DER feeding, food scale, reassessment |

## Translational Value

The batch is ready to power at least three Research Workspace tasks:

1. **Feline obesity model endpoint matrix**
   - Primary value: map body condition, insulin sensitivity, glucose handling, GLUT4, adipokines, metabolomics, microbiota, and cardiac morphology into one endpoint framework.
   - Best source anchors: `src-obesity-008`, `src-obesity-027`, `src-obesity-030`, `src-obesity-049`, `src-obesity-066`.

2. **Obesity-to-diabetes progression evidence map**
   - Primary value: prevent the false linear story that obesity or insulin resistance alone predicts diabetes.
   - Best source anchors: `src-diabetes-028`, `src-obesity-008`, `src-diabetes-005`.

3. **Feline obesity prevention and clinical pathway**
   - Primary value: shift from adult obesity treatment to post-gonadectomy kitten prevention and monitoring.
   - Best source anchor: `src-obesity-005`; supporting context from mechanism and phenotype papers.

## Gaps And Next Moves

| Gap | Why It Matters | Next Move |
|---|---|---|
| `src-obesity-022` correct deep extract missing | Gene-expression title remains unprocessed because the supplied body duplicated `src-obesity-008` | obtain correct deep extract before upgrading |
| Full paragraph / figure anchors not complete | Current `source_passages` are enough for initial trace, but not yet original-page paragraph-level audit | add article paragraph / table / figure anchors for high-visibility outputs |
| `src-obesity-027` full-article method details still thin | GLUT4 endpoint is important but current extraction notes a full Elsevier article audit gap | audit biopsy sites, diet, Western blot normalization, and exact protein-change details |
| MHO/MUO remains research-defined | `src-obesity-030` and `src-obesity-049` use small exploratory cohorts | label as research phenotype, not clinical class |
| Prevention review is not an intervention trial | `src-obesity-005` is a review with nutrition-industry conflict disclosures | keep DER / nutrient ranges as expert synthesis unless supported by primary trials |
| Cardiac morphology study is small and observational | `src-obesity-066` has no stable-weight control and one possible primary HCM case | use as interpretation context, not causation |

## Recommended Research Workspace Output Shape

For any third-batch obesity question, the output should use this structure:

1. **Research task**
   - Example: "Which endpoints matter when evaluating feline obesity and obesity-to-diabetes risk?"

2. **Evidence scope**
   - Include 9 processed sources, flag `src-obesity-022` as blocked.

3. **Core judgments**
   - Use the judgment statements above; cite source cards and passage snippets.

4. **Evidence map**
   - Cluster by mechanism / phenotype / inflammation / cardiac / prevention, not by chronology.

5. **Methods and endpoints**
   - Promote endpoint inventory table.

6. **Translational value**
   - Split model endpoints, clinical interpretation, prevention workflow, and BD/client explanation.

7. **Evidence boundaries**
   - State which claims are direct source facts, source-supported conclusions, and analysis inferences.

8. **Next research moves**
   - Correct `src-obesity-022`; add original paragraph anchors; generate a gold-standard `obesity_insulin_resistance` Research Workspace sample.

## Review Decision

The third batch is **Research Workspace ready for evidence-map and endpoint-matrix work**, with one blocked source and several explicit evidence-boundary constraints.

Do not use this batch as a direct owner-facing obesity management guide without adding guideline / clinical management sources (`src-obesity-003`, `src-obesity-006`, or equivalent) and separating kitten prevention from adult treatment.
